NCT05352828View on ClinicalTrials.gov

Autologous CD30.CAR-T in Combination With Nivolumab in cHL Patients After Failure of Frontline Therapy

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

July 25, 2022

Primary Completion Date

December 15, 2025

Study Completion Date

December 15, 2037

Conditions
Classical Hodgkin LymphomaHodgkin Disease RefractoryHodgkin Disease Recurrent
Interventions
DRUG

Nivolumab

Dose: 480 mg or 6 mg/kg Q4W

DRUG

Autologous CD30.CAR-T

Dose: 2 x 10e8 cells/m2

DRUG

Fludarabine

Dose: 30 mg/m2/day x 3 days

DRUG

Bendamustine

Dose: 70 mg/m2/day x 3 days

Trial Locations (5)

27599

UNC Lineberger Comprehensive Cancer Center, Chapel Hill

33136

University of Miami, Miami

77030

Baylor College of Medicine, Houston

MD Anderson Cancer Center, Houston

91010

City of Hope National Medical Center, Duarte

Sponsors

Lead Sponsor

Tessa Therapeutics

Collaborators (1)

Bristol-Myers Squibb
All Listed Sponsors
collaborator

Bristol-Myers Squibb

INDUSTRY

lead

Tessa Therapeutics

INDUSTRY

NCT05352828 - Autologous CD30.CAR-T in Combination With Nivolumab in cHL Patients After Failure of Frontline Therapy | Biotech Hunter | Biotech Hunter